SHINVA新华品牌怎么样 申请店铺

我要投票 SHINVA新华在医疗器械行业中的票数:938 更新时间:2026-02-13
SHINVA新华是哪个国家的品牌?「SHINVA新华」是 山东新华医疗器械股份有限公司 旗下著名品牌。该品牌发源于山东,由创始人许尚峰在1993期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力SHINVA新华品牌出海!将品牌入驻外推网,定制SHINVA新华品牌推广信息,可以显著提高SHINVA新华产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

SHINVA新华怎么样

2002年9月,山东新华医疗器械股份有限公司在上海证券交易所上市,现为中国医疗器械行业协会会长单位。

山东新华医疗器械股份有限公司始终坚持拼搏诚信的齐鲁文化、以用户为中心的现代企业文化为企业核心价值观,用目标鼓舞士气,用发展凝聚人心,用创新提升素质,用文化打造实力,坚定不移地走健康产业之路,坚定不移地走技术创新之路,坚定不移地走资本运作之路,拥有医疗器械及装备、制药装备、医疗服务三大业务板块。

在医疗器械板块,已形成九大配置精良、技术完备的先进产品线,涵盖感染控制、放疗及影像、手术器械及骨科、手术室工程及设备、口腔设备及耗材、体外诊断试剂及仪器、生物材料及耗材、透析设备及耗材、医用环保及其他领域。

制药装备板块,由生物制药、特种输液、中药制剂、固体制剂四大工程技术中心组成,下设八个产品技术分厂和五个控股公司,集制药装备研发、制造及销售为一体。在常规制药装备生产之外,提供着“制药工艺、制药装备、制药工程”三位一体的优质服务;同时,为化学药、生物药、植物药工厂的建设提供整包服务,为客户解决一切后顾之忧。

在医疗服务领域,新华医疗持续提升着品牌竞争力和美誉度。凭借专业的投资、建设、运营及采购和服务平台,打造具有先进医疗理念、前沿科研水平、品牌经营连锁、资源有机融合的现代化医院集团。与此同时,新华医疗也在积极拓展着肾脏健康服务,利用公司专业化、集约化、连锁化的运营优势,为医院提供新技术、新管理、新模式,创建出一系列特色鲜明的肾脏病专科医院和血液透析中心,用无限的责任感和专业度,服务于广大肾病患者。未来,新华医疗,将以集团化、专业化、规范化的全新面貌,为更多患者提供完善医疗服务,成就发展健康产业之路的宏伟梦想。

公司以山东核心区域为研发、制造、营销和管理总部,同时有北京核心区域、上海核心区域。

心系健康,诚信天下。站在新的历史起点上,面对新的发展机遇,新华医疗将一如既往,与时俱进,以自信、创新和拼搏,去勇敢面对困难和挑战,为人类健康事业、为铸造中国医疗器械产业的丰碑、打造世界知名医疗器械生产企业而继续努力奋斗!

In September 2002, Shandong Xinhua medical device Co., Ltd. was listed on the Shanghai Stock Exchange and is now the chairman of China Medical Device Industry Association. Shandong Xinhua Medical Equipment Co., Ltd. always adheres to the Qilu culture of striving for integrity, the modern enterprise culture centered on users as the core values of the enterprise, encourages morale with goals, rallies people with development, improves quality with innovation, builds strength with culture, firmly takes the road of health industry, firmly takes the road of technological innovation, and firmly takes the road of capital The way of operation, with medical devices and equipment, pharmaceutical equipment, medical services three business sectors. In the medical equipment sector, nine advanced product lines with excellent configuration and complete technology have been formed, covering infection control, radiotherapy and imaging, surgical equipment and orthopedics, operating room engineering and equipment, oral equipment and consumables, in vitro diagnostic reagents and instruments, biomaterials and consumables, dialysis equipment and consumables, medical environmental protection and other fields. The pharmaceutical equipment sector is composed of four engineering technology centers, including biopharmaceutical, special infusion, traditional Chinese medicine preparation and solid preparation. It has eight product technology branches and five holding companies, integrating the R & D, manufacturing and sales of pharmaceutical equipment. In addition to the production of conventional pharmaceutical equipment, it provides the high-quality service of "pharmaceutical technology, pharmaceutical equipment, pharmaceutical engineering"; at the same time, it provides the whole package service for the construction of chemical medicine, biological medicine, plant medicine factories, and solves all the worries for customers. In the field of medical services, Xinhua medical continues to enhance its brand competitiveness and reputation. With professional investment, construction, operation, procurement and service platform, we will build a modern hospital group with advanced medical concept, cutting-edge scientific research level, brand management chain and organic integration of resources. At the same time, Xinhua medical is also actively expanding kidney health services, taking advantage of the company's professional, intensive and chain operation advantages to provide new technology, new management and new mode for the hospital, creating a series of distinctive kidney disease specialized hospitals and hemodialysis centers, serving the vast number of nephrotic patients with unlimited sense of responsibility and professionalism. In the future, Xinhua medical will take a new look of collectivization, specialization and standardization to provide more patients with perfect medical services and achieve the grand dream of developing health industry. The company takes the core area of Shandong Province as its R & D, manufacturing, marketing and management headquarters, and has the core areas of Beijing and Shanghai. Heart health, integrity world. Standing at a new historical starting point and facing new development opportunities, Xinhua medical will, as always, keep pace with the times, bravely face difficulties and challenges with self-confidence, innovation and hard work, and continue to strive for the cause of human health, the building of a monument of China's medical device industry and the building of a world-famous medical device manufacturer!

本文链接: https://brand.waitui.com/f0c49f885.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

人民币汇率升破6.90,盘中创近三年来新高

2月12日,在岸、离岸人民币对美元汇率双双升破6.90关口,盘中创下2023年4月以来新高。从市场归因来看,结汇盘集中释放是本轮人民币走强的核心驱动力。东方金诚首席宏观分析师王青表示,年末企业结汇需求季节性增加,叠加近期人民币持续升值,此前出口高增所累积的结汇需求有可能加速释放。(上证报)

38分钟前

新基金发行火热,公募备战节后行情

2026开年以来,新基金发行火热。1月新基金发行数量达169只,达到2023年3月以来的最高水平。多只基金一日售罄,还有产品因超募触发比例配售。此外,时隔三年,市场又出现了70亿元级别的主动权益新产品。尽管春节假期临近,但在新基金发行升温的氛围下,机构已开始提前布局春节后的行情,一方面基金公司在节前启动新发,筹备节后推广;另一方面,渠道也在提前布局,抢占节后发行先机。(中证网)

38分钟前

纯债基金发行降至冰点,“固收+”稳居主力地位

2026年以来,债券型基金发行整体遇冷,规模同比显著下滑,其中新发纯债基金只有寥寥数只。与之形成鲜明对比的是,“固收+”基金延续了2025年强势崛起的态势,在新发债基中占据主导地位。业内人士认为,未来居民与机构的配置需求将持续为“固收+”基金发展提供支撑,其在稳健理财领域的地位有望进一步巩固,但与此同时,行业也将面临债市收益承压、产品竞争加剧等多重挑战。(上证报)

38分钟前

调仓换基增配价值品种,基金投顾开年布局求稳

2026开年以来,基金投顾调仓节奏明显加快。统计数据显示,今年1月,近650个基金投顾组合中,有178个进行调仓,增配低估值价值型基金成为共识,永赢融安、华泰柏瑞红利低波ETF联接等产品获基金投顾增配比例最高。在大类资产配置层面,基金投顾组合普遍提升了A股及债券仓位,同步减配现金资产、美股及港股持仓;行业维度则增配有色金属、电子、通信,减配生物医药、汽车及银行。(中证网)

38分钟前

爱彼迎第四季度营收为28亿美元,同比增长12%

当地时间2月12日,爱彼迎公布第四季度及全年业绩报告。报告显示,第四季度爱彼迎营收为28亿美元,同比增长12%;第四季度净利润为3.41亿美元,净利润率为12%;第四季度预订总额为204亿美元,同比增长16%。2025年全年爱彼迎营收为122亿美元,同比增长10%;第四季度净利润为25亿美元,净利润率为21%;第四季度预订总额为913亿美元,同比增长12%。(界面)

38分钟前

本页详细列出关于SHINVA新华的品牌信息,含品牌所属公司介绍,SHINVA新华所处行业的品牌地位及优势。
咨询